TABLE 1.
N = 25 | Off acid blockade (N = 14) | On acid blockade (N = 11)* | |
---|---|---|---|
Female sex | 11 (44%) | 7 (50%) | 4 (36%) |
Age, years; median [IQR] | 13.8 [11.2–14.8] | 13.5 [11.2–14.7] | 13.8 [11.2–15.5] |
Genotype | |||
F508/F508 | 11 (44%) | 6 (43%) | 5 (45%) |
F508/other | 12 (48%) | 7 (50%) | 5 (45%) |
Other/other | 2 (8%) | 1 (7%) | 1 (9%) |
Race | |||
Caucasian | 24 (96) | 13 (93%) | 11 (100%) |
African American | 1 (4%) | 1 (7%) | 0 |
Hispanic or Latino Ethnicity | 3 (12%) | 2 (14%) | 1 (9%) |
BMI percentile, median [IQR] | 58 [37–78] | 63 [38–78] | 54 [33–76] |
FEV1% predicted, median [IQR] | 92 [85–100] | 96 [88–102] | 88 [85–94] |
On CFTR modulators | 15 (60%) | 9 (64%) | 6 (55%) |
On PPI medications | 11 (44%) | 6 (55%) |
Two individuals from the cross over study design are included.